首页> 外国专利> PROCEDURE FOR COMBINED MEDICAMENTOUS CORRECTION OF VASCULAR ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH DISEASES OF KIDNEYS

PROCEDURE FOR COMBINED MEDICAMENTOUS CORRECTION OF VASCULAR ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH DISEASES OF KIDNEYS

机译:肾脏疾病患者的合并血管内皮功能障碍的药物矫正程序

摘要

The procedure for the combined medicamentous correction of the vascular endothelial dysfunction in the patients with the diseases of kidneys provides for the biochemical examination of blood serum prior to the treatment, the assessment of the control indices of the vascular endothelial dysfunction, and the basic therapy. The concentration of nitrosothiol as the stable metabolite of nitric oxide (NO) is assessed as the control index of the functional state of the endothelium. The concentration of malonic dialdehyde (MDA) and SH groups is assessed as the index of the oxidative stress and the bioavailability of nitric oxide. MDA to SH groups is calculated. The content of interleukin-1? characterizes the anti-inflammatory activity. The control indices are assessed prior to the treatment and after two-week treatment. The decrease in the valuesassessed by less than 30% is an indication for the use of hypolipidemic drug, non-saturated fatty acids of omega-3 class at the therapeutically effective doses for the following two months.
机译:联合治疗肾脏疾病患者的血管内皮功能障碍的方法为治疗前的血清生化检查,评估血管内皮功能障碍的控制指标以及基础治疗提供了条件。作为稳定的一氧化氮(NO)代谢产物的亚硝基硫醇的浓度被评估为内皮功能状态的控制指标。丙二醛(MDA)和SH基团的浓度被评估为氧化应激和一氧化氮的生物利用度的指数。计算了SH组的MDA。 IL-1的含量?表征抗炎活性。在治疗前和治疗两周后评估对照指数。评估的值下降小于30%,表明在接下来的两个月中,以治疗有效剂量使用降血脂药,omega-3类的非饱和脂肪酸。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号